Discovery of 3-amino-4-chlorophenyl P1 as a novel and potent benzamidine mimic via solid-phase synthesis of an isoxazoline library

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 10, 2003, Pages 1795-1799

  Lam, Patrick Y S ^a   Adams, Jessica J ^a   Clark, Charles G ^a   Calhoun, W Jason ^a   Luettgen, Joseph M ^a   Knabb, Robert M ^a   Wexler, Ruth R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 4 CHLOROPHENYL; 4 CHLORO 3 ANILINE; ANILINE DERIVATIVE; BENZAMIDINE; BENZENE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; ISOXAZOLINE DERIVATIVE; LIGAND; UNCLASSIFIED DRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS;

EID: 0037687741     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00130-6     Document Type: Article

References (32)

1. (a) Rosenberg, J.S.; Beeler, D.L.; Rosenberg, R.D. Act. J. Biol. Chem. 1995, 250, 1607.
2. (b) Davre, E.W.; Fujikawa, K.; Kisiel, W.T. Biochem. 1991, 30, 10363.
3. Rosenberg R.D., Damus P.S. J. Biol. Chem. 248:1973;6498.
4. Mann K. G., Nesheim M. E., Church W. R., Haley P., Krishnaswamy S. Blood. 76:1990;1.
5. (a) Wong P. C., Quan M. L., Crain E. J., Watson C. A., Wexler R. R., Knabb R. M. J. Pharm. Exper. Therap. 292:2000;351.
6. (b) Wong P. C., Crain E. J., Knabb R. M., Meade R. P., Quan M. L., Watson C. A., Wexler R. R., Wright M. R., Slee A. M. ibid. 295:2000;212.
7. Murayama N., Tanaka M., Kunitada S., Yamada H., Inoue T., Terada Y., Fujita M., Ikeda Y. Clin. Pharm. Therap. 66:2000;258.
8. (a) For reviews and references see: Vacca J. P. Thrombosis and Coagulation. In Annual Reports in Med. Chem., Bristol, J. A. Ed. Academic Press, 1998, 33, pp 81-90.
9. (b) Fevig, J. M.; Wexler, R. R. Annual Reports in Med. Chem., Doherty, A. M. Ed. Academic Press, 1999, 34, pp 81-100.
10. (c) Zhu B.-Y., Scarborough R.M. ibid. 35:2000;83
11. (d) Sanderson P.E.J. ibid. 36:2001;79.
12. (a) For reviews specifically on nonbenzamidines see: Menear K. Curr. Med. Chem. 5:1998;457
13. (b) Rewinkel J.B.M., Adang A.E.P. Cur. Pharm. Design. 5:1999;1043
14. (c) Peterlin-Masic L., Kikelj D. Tetrahedron. 57:2001;7073.
15. Pinto D.J., Orwat M.J., Wang S., Fevig J.M., Quan M.L., Amparo E., Cacciola J., Rossi K.A., Alexander R.S., Wong P.C., Knabb R.M., Luettgen J.M., Aungst B.J., Li L., Wright M., Jona J.A., Wexler R.R., Lam P.Y.S. J. Med. Chem. 44:2001;566.
16. Lam, P. Y. S.; Clark, C. G.; Li, R.; Pinto, D. J. P.; Orwat, M. J.; Galemmo, R. J.; Fevig, J. M.; Alexander, R. S.; Smallwood, A. M.; Rossi, K. A.; Wright, M. R.; Bai, S.; He, K.; Luettgen, J. M.; Wong, P. C.; Knabb, R. M.; Wexler, R. R. Submitted to J. Med. Chem.
17. (a) Quan M.L., Pruitt J.R., Ellis C.D., Liauw A.Y., Galemmo R.A., Stouten P.F.W., Wityak J., Knabb R.M., Thoolen M.J., Wong P.C., Wexler R.R. Bioorg. Med. Chem. Lett. 7:1997;2813
18. (b) Quan M.J., Liauw A.Y., Ellis C.D., Pruitt J.R., Bostrom L.L., Carini D.J., Huang P.P., Harrison K., Knabb R.M., Thoolen M.J., Wong P.C., Wexler R.R. J. Med. Chem. 42:1999;2752
19. (c) Quan M.J., Ellis C.D., Liauw A.Y., Alexander R., Knabb R.M., Lam G.N., Wong P.C., Wexler R.R. J. Med. Chem. 42:1999;2760
20. (d) Quan M.L., Wexler R.R. Curr. Top. Med. Chem. 1:2001;137.
21. During the course of our investigation, two isoxazoline library syntheses were reported. Solid phase: Cheng J.-F., Mjalli A.M.M. Tetrahedron Lett. 39:1998;939.
22. Fluorous phase: Studer A., Curran D.P. Tetrahedron. 53:1997;6681.
23. Representative procedure: 4-Chloro-3-nitrobenzaldehyde (279 mg, 1.5 mmol) was placed in a 4 mL plastic vial with an internal filter and a drain plug. Ethanol (2.5 mL) was added followed by the addition of an aqueous hydroxylamine hydrochloride solution (0.50 mL, 1.8 mmol, 3.74 M) and an aqueous sodium acetate solution (0.79 mL, 1.2 mmol, 1.52 M). The vial was rotated for 12 h on a Barnstead/Thermolyne Labquake Rotator. The ethanol and water are removed under a stream of nitrogen leaving a solid that was washed once with water and dried under dynamic vacuum to give 4-chloro-3-nitro-benzaldehyde oxime.
24. -1.
25. DeGrado W.F., Kaiser E.T. J. Org. Chem. 47:1982;3258.
26. -1.
27. Quan M.J., Liauw A.Y., Ellis C.D., Pruitt J.R., Bostrom L.L., Carini D.J., Huang P.P., Harrison K., Knabb R.M., Thoolen M.J., Wong P.C., Wexler R.R. J. Med. Chem. 42:1999;2752.
28. 18 (5.00 g, 16.4 mmol) was heated to reflux in trifluoroacetic acid (80 mL) for 7 h. The solvent was evaporated and the solid judged to be of sufficient purity for further use.
29. 2O in refluxing ethyl acetate.
30. (a) Quan M.L., Ellis C.D., He M.Y., Liauw A.Y., Woerner F.J., Alexander R.S., Knabb R.M., Lam P.Y.S., Luettgen J.M., Wong P.C., Wright M.R., Wexler R.R. Bioorg. Med. Chem. Lett. 13:2003;369
31. (b) Quan M.L., Ellis C.D., He M.Y., Liauw A.Y., Lam P.Y.S., Rossi K.A., Knabb R.M., Luettgen J.M., Wright M.R., Wong P.C., Wexler R.R. Bioorg. Med. Chem. Lett. 13:2003;1023.
32. The 3-amino-4-chlorophenyl P1 moiety was incorporated into an analogous series and the pharmacokinetic profile examined in dog. This compound was found to be highly bioavailable (71%).